Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Prof. Petr Widimsky ,
Interventional cardiology has matured into a major subspeciality within cardiology. Its successes - especially in the treatment of acute myocardial infarction and unstable angina pectoris - have changed clinical cardiology entirely. Interventional cardiology is approaching its "30th birthday" this year. This is a reason to look back and remember the "milestones".
The first introduction of a catheter to the human heart was performed by Dr. Werner Forsmann in Eberswalde (Germany) in 1929. Dr. Forsmann introduced a catheter to his own heart following a therapeutic idea, that this method would allow intracardiac administration of medications . The world‘s first diagnostic cardiac catheterisation in patients (n = 11) was successfully performed by Dr. Otto Klein in the University Hospital Prague (Czechoslovakia) in 1930 .
It took 26 additional years before this diagnostic method became widely recognised thanks to Andre Cournand, who was awarded (along with W. Forsmann and C. Richards) the Nobel Prize in 1956 .
The original (Forsmann’s) idea of therapeutic cardiac catheterisation was re-vitalised 48 years later, in 1977, by Dr. Andreas Grüntzig - a young (born in Dresden, June 25, 1939) German physician, working in the Kantonspital Zürich, Switzerland. He modified the angioplasty balloon first developed by W. Portmann in 1973 for peripheral arteries . Andreas Grüntzig (fig. 1) recognised the potential of the balloon catheter and developed the double lumen ("over-the-wire“) angioplasty balloon. He tested this balloon in animal experiments and first applied it to a patient with proximal left anterior descending coronary artery stenosis on September 16, 1977 [5, 6]. This procedure was so successful, that this first angioplasty patient outlived his doctor: while Andreas Grüntzig died with his wife in a private plane crash (in Forsyth, Georgia, October 27, 1985), his first patient remained asymptomatic and was talking about his experience 20 years later – at a special symposium held in 1997 in Zürich celebrating the 20th anniversary of the first angioplasty. During the initial cca 5 years (1977-82) percutaneous transluminal coronary angioplasty (PTCA, name given to this method by A. Grüntzig) had technical success rates of 50-60% (and this was when only proximal type "A" lesions in stable patients were approached). Simultaneously, complication rates were initially high: mortality 1-2%, non-fatal MI 5%, emergency CABG 6%. These results substantially improved during the subsequent years despite the fact that more complex lesions and more severely ill patients were being treated (table 1). The two main limitations of “plain old balloon angioplasty“ were restenosis after balloon dilatation (angiographically present in 30-50%) and abrupt vessel closure due to major dissection or thrombus (5-10%). Both these problems have been approached by several methods, but only one of them gained large clinical recognition: coronary stents. The first stent in humans was implanted by Ulrich Sigwart and co-workers . This was a self-expandable "Wallstent", later abandoned due to a high rate of stent thrombosis or restenosis. Instead, balloon-expandable stents have gained wide acceptance in the subsequent years. However, it took almost 10 years before stents could be used for the vast majority of patients treated by angioplasty. The reason was high incidence of acute / subacute stent thrombosis (8%) and of severe bleeding complications (5-10%) with the old antithrombotic regimen (heparin + aspirin + dipyridamol + warfarin + dextran) used before 1994. It was the introduction of high pressure inflation (" stent oversizing" under the guidance of intravascular ultrasound) and of thienopyridines (ticlopidin or later clopidogrel replaced warfarin + dipyridamol + dextran), that changed coronary stents into a current routine and safe device [8, 9]. The procedure is now called percutaneous coronary intervention (PCI). Highly flexible, balloon-expandable coronary stents combined with effective and safe antithrombotic therapy made possible the true “invasion” of interventional cardiology to the area, originally considered as contraindication: for the treatment of acute myocardial infarction. After initial attempts with intracoronary thrombolysis , angioplasty was proved to be the most effective strategy for ST elevation acute myocardial infarction . While the original indication for PCI (chronic stable angina pectoris) remains even after 30 years only symptomatic indication (PCI was never shown to improve prognosis of these patients – last evidence provided by the COURAGE trial – ref. 12), the original contraindication of PCI (acute coronary syndromes, especially acute myocardial infarction) became today the main indication for PCI (and is a prognostic indication). Thus, a 30 year-old subspeciality, interventional cardiology is one of the key parts of modern cardiology, saving the many lives of patients with acute myocardial infarction or unstable angina pectoris and improving the quality of life of patients with chronic stable angina pectoris. PTCA / PCI history is a European success story: most of the pioneer work cited above was done in Europe by European cardiologists. The improving cooperation between the European Society of Cardiology – European Association of PCI (EAPCI, represented by William Wijns) - largest educational meeting in the field (EuroPCR, Jean Marco) - the new journal (EuroIntervention, Patrick Serruys) opens great opportunities for the near future.
Note: It was the intention of the author not to discuss here the latest achievement in the field – drug eluting stents. It is too early to place this promising and still evolving tool in the history of our subspecialty. Only the future will tell.
Table 1: Angioplasty indications and success rates evolution over 30 years.
Table 2: Major contributions of European cardiologists to the development of interventional cardiology.
Fig. 1: Dr. Andreas Grüntzig
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Forsmann W. Die Sondierung des rechten Herzens. Klin Wochenschr 1929; 8: 2085. 2. Klein O. Zur Bestimmung des zerkulatorischen minutens Volumen nach dem Fickschen Prinzip. Munch Med Wochenschr 1930; 77: 1311. 3. Cournand AF. Nobel lecture, December 11, 1956. In: Nobel lectures, Physiology and Medicine 1942-1962. Elsevier Publishing, Amsterdam, 1964, p. 529. 4. Portmann W. Ein neuer Korsett-Ballonkatheter zur transluminalen Rekanalization nach Dotter unter besonderer Berucksichtigung von Obliterationen an den Beckenarterien. Radiol Diagn 1973; 14: 239. 5. Grüntzig A. Transluminal dilation of coronary artery stenosis. Lancet 1978; 1: 263-263. 6. Grüntzig A, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenoses. Percutaneous transluminal coronary angioplasty. N Engl J Med 1979; 301: 61. 7. Sigwart U, Puel J, Mirkovitch V. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987; 316: 701-6. 8. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995; 91: 1676-1688. 9. Schomig A, Neumann FJ, Kastrati A. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084. 10. Chazov EL, Matveeva LS, Mazaev AV. Intracoronary administration of fibrinolysis in acute myocardial infarction. Ter Arkh 1976; 48: 8-19. 11. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993; 328: 680-4. 12. Boden WE et al. on behalf of the COURAGE Trial Research group. Optimal Medical Therapy with or without PCI for Stable Coronary Disease. N Engl J Med 2007; 356: online 10.1056/NEJMoa070829.
Prof. P. Widimsky, Charles University Prague, Czech Republic. Chairman of the ESC Credentials Committee
Our Mission: To Reduce the Burden of Cardiovascular Disease
© 2019 European Society of Cardiology. All rights reserved